Ibrutinib is a small molecule that functions as a irreversible potent inhibitor of Burton’s tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, including chronic lymphocytic leukemia (CLL), Waldenström’s Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Imbruvica and ibrutinibum. Its PubChem CID is 24821094.
Ibrutinib
| CAS No | 936563-96-1 |
|---|---|
| Molecular Formula | C25H24N6O2 |
| Molecular Weight | 440.5 g/mol |
| Synonyms | 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ibrutinib is a small molecule that functions as a irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials.
The listed CAS number is 936563-96-1.
The listed molecular formula is C25H24N6O2.
The listed molecular weight is 440.5 g/mol.
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one.
The source lists Imbruvica and ibrutinibum.